BioCentury
ARTICLE | Emerging Company Profile

Biolipox: Arachidonic acid rocks

June 10, 2002 7:00 AM UTC

Among the many biotech companies spun out of Sweden's Karolinska Institutet in the past few years years, Biolipox AB has operated in stealth mode. Its scientific platform, based on the discovery of a novel metabolic pathway in humans, has been kept secret while the company worked to advance its technology without spurring competition. But now that it has small molecule leads against two targets, the company is seeking a higher profile in order to broaden its base through collaborations and in-licensing.

"Our key asset, a novel arachidonic acid metabolism, has not been published yet," CEO Carl-Johan Dalsgaard said. "So far as we know, this pathway is unique to humans - at least, we don't find it in conventional lab animals like mice, rats and rabbits - and it is involved in the development of inflammatory states."...